CA2973540C - Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant - Google Patents

Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant

Info

Publication number
CA2973540C
CA2973540C CA2973540A CA2973540A CA2973540C CA 2973540 C CA2973540 C CA 2973540C CA 2973540 A CA2973540 A CA 2973540A CA 2973540 A CA2973540 A CA 2973540A CA 2973540 C CA2973540 C CA 2973540C
Authority
CA
Canada
Prior art keywords
siponimod
day
administration
regimen
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2973540A
Other languages
English (en)
Other versions
CA2973540A1 (fr
Inventor
Eric Legangneux
Alexandros Sagkriotis
Pierre Jordaan
Florine Polus
Kasra Shakeri-Nejad
Alan John Camm
Shibadas Biswal
Parasar Pal
Uday Kiran Veldandi
Atul Keshav Pawar
Vassilios Aslanis
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority claimed from PCT/IB2016/051004 external-priority patent/WO2016135644A1/fr
Publication of CA2973540A1 publication Critical patent/CA2973540A1/fr
Application granted granted Critical
Publication of CA2973540C publication Critical patent/CA2973540C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Il est décrit des méthodes de traitement de maladies auto-immunes avec du siponimod chez des patients recevant en outre un bêta-bloquant. Selon certaines réalisations, le siponimod est administré dans le cadre d’un schéma d’adaptation posologique initial, suivi d’un schéma dans lequel le bêta-bloquant est ajouté au traitement du patient au plus tôt le premier jour d’un traitement d’entretien.
CA2973540A 2015-02-26 2016-02-24 Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant Active CA2973540C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN559/DEL/2015 2015-02-26
IN559DE2015 2015-02-26
PCT/IB2016/051004 WO2016135644A1 (fr) 2015-02-26 2016-02-24 Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant

Publications (2)

Publication Number Publication Date
CA2973540A1 CA2973540A1 (fr) 2016-09-01
CA2973540C true CA2973540C (fr) 2025-07-08

Family

ID=

Similar Documents

Publication Publication Date Title
US12533340B2 (en) Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3287124B1 (fr) Forme posologique orale de kétamine
EP3641742B1 (fr) Hydroxynorkétamine destinée à être utilisée dans le traitement de la dépression
US20250041266A1 (en) S1p modulator immediate release dosage regimen
AU2020203874B2 (en) Methods and compositions for treating depression using cyclobenzaprine
US20230157947A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
US20240197756A1 (en) Methods of treatment with neuroactive steroids
CA2973540C (fr) Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant
WO2022129932A1 (fr) Compositions orales comprenant de la kétamine combinée à de la kétamine sous-cutanée ou intraveineuse pour utilisation dans le traitement, le contrôle ou la prévention des troubles dépressifs
US20110027324A1 (en) O-desmethyl-venlafaxine for treating major depressive disorder
KR20240165974A (ko) 다계통 위축증 치료에서의 사용을 위한 암플렐록세틴
JP2022540854A (ja) 疼痛を緩和するためのイブプロフェン及びトラマドールの組合せ
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases